Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any dysequilibrium syndrome in which the cause of the disease is a mutation in the ATP8A2 gene.
Features include always present findings: Truncal ataxia, Corpus callosum atrophy, Shrinkage of the cerebellum (cerebellar atrophy), and Cerebral cortical atrophy and others; and sometimes findings: Inability to walk. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 | Inability to walk, Truncal ataxia, Cerebral cortical atrophy |
Muscles | 3 | Corpus callosum atrophy, Shrinkage of the cerebellum (cerebellar atrophy), Cerebral cortical atrophy |
ATP8A2 encodes ATPase phospholipid transporting 8A2 (1,188 aa). Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Highest expression in Brain Cerebellar Hemisphere (42.7 TPM) and Brain Cerebellum (35.8 TPM).
Cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4 is associated with mutations in the ATP8A2 gene on chromosome 13.
ATP8A2 is classified as a druggable target (Enzyme and Transporter categories) with score 0.0.
Genetic testing for ATP8A2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4.
4 publications have been identified in PubMed for cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4. Research spans Basic Science / Preclinical (50%), Diagnostic / Biomarker (25%), and Case Report / Case Series (25%).
Jawabri AA (2026). [PMID: 42051465](https://pubmed.ncbi.nlm.nih.gov/42051465/). *Hum Mutat*. [Case Report / Case Series]
Al-Hedaithy A (2025). [PMID: 39747233](https://pubmed.ncbi.nlm.nih.gov/39747233/). *Sci Rep*. [Diagnostic / Biomarker]
Matsell E (2025). [PMID: 39662833](https://pubmed.ncbi.nlm.nih.gov/39662833/). *J Biol Chem*. [Basic Science / Preclinical]
Kaiyrzhanov R (2024). [PMID: 38581205](https://pubmed.ncbi.nlm.nih.gov/38581205/). *Mov Disord*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:34 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 4